An in vitro-in vivo correlation study of modified release formulations of Venlafaxine.HCl

A single dose, randomized, complete and four treatment cross over study was conducted in healthy human subjects for IVIVC of venlafaxine.HCl, Plasma concentrations were estimated by a simple, rapid, sensitive and validated LCMS method, Cetirizine was used as the internal standard (IS), The analytes...

Ամբողջական նկարագրություն

Պահպանված է:
Մատենագիտական մանրամասներ
Հիմնական հեղինակներ: Aravindaraj, J.R (Հեղինակ), Manikandan, D. (Հեղինակ), Nanjan, Moola Joghee (Հեղինակ)
Ձևաչափ: Գիրք
Հրապարակվել է: São Paulo State University (UNESP), 2014-09-01T00:00:00Z.
Խորագրեր:
Առցանց հասանելիություն:Connect to this object online.
Ցուցիչներ: Ավելացրեք ցուցիչ
Չկան պիտակներ, Եղեք առաջինը, ով նշում է այս գրառումը!

MARC

LEADER 00000 am a22000003u 4500
001 doaj_8db058e3abbc4f11bc64d33008f17d22
042 |a dc 
100 1 0 |a Aravindaraj, J.R.  |e author 
700 1 0 |a Manikandan, D.  |e author 
700 1 0 |a Nanjan, Moola Joghee  |e author 
245 0 0 |a An in vitro-in vivo correlation study of modified release formulations of Venlafaxine.HCl 
260 |b São Paulo State University (UNESP),   |c 2014-09-01T00:00:00Z. 
500 |a 1808-4532 
500 |a 2179-443X 
520 |a A single dose, randomized, complete and four treatment cross over study was conducted in healthy human subjects for IVIVC of venlafaxine.HCl, Plasma concentrations were estimated by a simple, rapid, sensitive and validated LCMS method, Cetirizine was used as the internal standard (IS), The analytes and the IS were extracted from the human plasma by liquid-liquid extraction technique, The reconstituted samples were chromatographed on Kromasil C18 column using an isocratic solvent mixture [acetonitrile-water, 90:10 (v/v)] at a flow rate of 0.5 mL/min, Method validation was performed as per FDA guidelines and the results met the acceptance criteria, USP dissolution apparatus I (Basket) and pH 6.8 at 100 rpm was found to yield acceptable IVIVC for the drug, The developed dissolution method would discriminate bioinequivalent batches, A 'Level A' correlation was observed for the selected formulations at the in vitro dissolution conditions developed, The dissolution method predicted the best absorption rate for the selected modified release formulations, The validity of the correlation was assessed by determining how well the IVIVC model could predict the rate and the extent of absorption as characterized by Cmax and AUC, A percent prediction error of = 10 % for C max and AUC obtained establishes the predictability of the developed IVIVC model, It may, therefore, be concluded that the developed dissolution method can surrogate for human bioequivalence study. 
546 |a EN 
690 |a IVIVC 
690 |a Bioequivalence 
690 |a Dissolution 
690 |a Human plasma 
690 |a Venlafaxine 
690 |a HCl 
690 |a Pharmaceutical industry 
690 |a HD9665-9675 
690 |a Pharmacy and materia medica 
690 |a RS1-441 
655 7 |a article  |2 local 
786 0 |n Revista de Ciências Farmacêuticas Básica e Aplicada, Vol 34, Iss 4, Pp 565-576 (2014) 
787 0 |n http://serv-bib.fcfar.unesp.br/seer/index.php/Cien_Farm/article/view/3246/3246 
787 0 |n https://doaj.org/toc/1808-4532 
787 0 |n https://doaj.org/toc/2179-443X 
856 4 1 |u https://doaj.org/article/8db058e3abbc4f11bc64d33008f17d22  |z Connect to this object online.